Dated December 26, 2019 CONVERTIBLE BONDS SUBSCRIPTION AGREEMENT between INOVIO PHARMACEUTICALS, INC. - Company - and The Overseas Growth Fund I - Investor -Convertible Bonds Subscription Agreement • January 2nd, 2020 • Inovio Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus • New York
Subject to the terms of the Indenture, by executing and delivering this Fundamental Change Repurchase Notice, the undersigned Holder of the Bonds identified below is exercising its Fundamental Change Repurchase Right with respect to (check one):
Inovio Pharmaceuticals, Inc. KRW4,700,000,000 1.00% Convertible Bonds due 2024 Registration Rights AgreementRegistration Rights Agreement • January 2nd, 2020 • Inovio Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus • New York
Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you, its 1.00% Convertible Bonds due 2024 (the “Bonds”), in the amounts and upon the terms set forth in the Subscription Agreement by and between the Company and the purchasers named therein, dated as of December 26, 2019 (the “Subscription Agreement”), relating to the offer and sale of the Bonds (the “Offering”). In certain circumstances, the Bonds will be convertible into shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) or Korea Depository Receipts (“KDRs”) representing Common Stock if, on the relevant conversion date, the Company has KDRs listed on the KOSDAQ Market of the Korea Exchange (“KOSDAQ”), in each case, in accordance with the terms of the Bonds and the Subscription Agreement. To induce you to enter into the Subscription Agreement and to satisfy your obligations thereunder, you and your Affiliates that are holders of the Bonds from time
